Home » Clinical Trials » Location » France
Marseille Cedex 5, France Clinical Trials
A listing of Marseille Cedex 5, France clinical trials actively recruiting patients volunteers.
Found (129) clinical trials
PASS OCT Post-market Clinical Follow-up
The primary endpoint is to evaluate the safety of the PASS OCT system. The secondary endpoints are to analyze the efficacy of the system with several point of view: The quality of fusion and the time of fusion through X rays the pain with VAS the quality of life thanks ...
0.0 miles
French Registry of First-line Treatment of Acute Promyelocytic Leukemia
Collection of epidemiological data on non-high-risk APL patients aged 70 years: age and sex distribution, medical history, prognostic factors (time to treatment start, severity of coagulopathy at presentation, Performance status). Documentation of clinical and biologic effectiveness of the two first-line treatment approaches available for non-high-risk APL patients. Documentation of Minimal ...
0.0 miles
Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting
Patients will be enrolled when they start a treatment with Sutent in 1st line or Inlyta in 2nd line post Sutent treatment. The possible sequences of treatment under investigation will be Sutent (prospective) - Inlyta Sutent (retrospective) - Inlyta Sutent - not further active treatment (supportive care) Sutent - other ...
0.0 miles
Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants
The management of critical situations is difficult for several reasons: - First, there is significant intra- and inter-individual variability in the pharmacokinetics of NOACs, which is further heightened in the critical setting by drug interactions with other agents that interfere with P-GP (P-GLYCOPROTEIN)and cytochrome P4503A4 in patients who are often ...
0.0 miles
Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease. Patients with Cushing's disease and treated with pasireotide s.c. alone and in combination with other therapies will be monitored. For this study, ...
0.0 miles
Clinical and Device Functional Assessment of Real World ICD Patients
For these reasons, it is very important to observe the clinical practice on a large variety of centers and countries, with the objective to collect long term safety and performance data in patients undergoing ICD/CRT-D device implantation (first implant, replacement or upgrade). The safety and performance of the ICDs can ...
0.0 miles
French Lumbar Total Disk Replacement Observational Study
Secondary objectives: The secondary objectives are: Describe the reasons for re-interventions operated floor and / or (x) level (s) adjacent (s) Describe the evolution of the function with the functional Oswestry score Describe the evolution of lumbar radicular pain by visual analog scale (VAS) Describe the evolution of the quality ...
0.0 miles
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
The study will capture post-marketing safety data on patients treated with eculizumab. Additionally, the study will collect information on the progression of disease in all patients.
0.0 miles
Product Surveillance Registry
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge ...
0.0 miles
A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.
0.0 miles